A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

Completed · Phase 1

Conditions studied: Atherosclerosis

In brief

This study is designed to assess the pharmacokinetics of darapladib and its metabolites following single and 28 days of repeat dosing of darapladib.

Key facts

Study ID
NCT00743860
Run by
GlaxoSmithKline
People needed
20
Starts
2008-09-01
Expected to finish
2008-12-01
Last updated by the study team
2016-11-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.